חוב לטווח ארוך: IGC Pharma (IGC)

Due to the humanitarian status of medicine, IGC Pharma, Inc. (IGC) scientific developments are shielded from trade conflicts in the US. The company is creating unique treatments for dementia by combining natural components with classical pharmacology. The market trend for long-term debt on the GURU.Markets platform stands at 0.00. Meanwhile, the biotechnology center is based in the US, while drug synthesis is fully delegated to external CDMO contractors.

For IGC Pharma, Inc. (IGC), which develops unique cannabinoid-based dementia therapies, the volume of borrowed capital determines the ability to fund costly R&D without losing control. An analysis of the company's long-term debt captures obligations with maturities exceeding one year, allowing investors to distinguish speculative noise from real business scaling and assess the debt load risk relative to sector competitors.